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Abstract Previously, we have shown that the NF1 gene gives
rise to multiple novel splice variants. In the present study, nine
NF1 variants were quanti¢ed by real-time PCR in various hu-
man tissues. Some of these variants were expressed at low to
moderate low levels and possible implications of these ¢ndings
are discussed. Interestingly, two variants (NF1-vE4b and NF1-
vE43) were shown to be highly expressed in speci¢c tissues.
NF1-vE43 lacks a nuclear targeting sequence and might be
functionally di¡erent from full-length NF1. These novel NF1
splice variants might expand our understanding of the role of
neuro¢bromin. - 2002 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Neuro¢bromatosis type 1 (NF1) is a common autosomal
dominant disorder a¡ecting V1 in 3000 individuals. NF1 is
fully penetrant and is notorious for its tremendous variable
clinical expression, even among members of the same family.
Although the NF1 protein product, neuro¢bromin, is ubiqui-
tously present, the main manifestations are neurocutaneous.
Patients present with cafe¤-au-lait spots, neuro¢bromas, iris
hamartomas (Lish nodules) and freckling of axillary and in-
guinal regions. Other manifestations include learning disabil-
ities, optic glioma, bone abnormalities and an increased risk
of speci¢c malignancies [1]. The NF1 gene spans V350 kb of
genomic DNA and produces a 11^13 kb transcript containing
60 exons [2^4].
Alternative splicing is an important mechanism whereby
di¡erent mRNAs are generated from the same gene, thus in-
creasing the coding capacity. It is often regulated in a tissue-
or developmental-speci¢c manner. Several alternative tran-
scripts have been described for the NF1 gene. Three alterna-
tive exons (9br, 23a and 48a) expand the size of the coding
region. These isoforms were also detected at the protein level
[5,6]. Four other transcripts have been reported (the deletion
of exon 29, exon 30, exon 29/30 and the N-isoform) which
would lead to truncated neuro¢bromins [7,8], but no further
con¢rmation at the protein level has been reported yet. Using
an RT-PCR plasmid library we determined the extent of alter-
native splicing in NF1 [9], and a survey of various new NF1
splice variants was described. In the present study, further
insight into the signi¢cance of some of these variants is pro-
vided by accurate quanti¢cation of variant transcript levels in
di¡erent human tissues. Isoform-speci¢c quanti¢cation using
real-time PCR [10] was applied to quantify nine NF1 tran-
scripts. Using this method, several variants were identi¢ed
that were highly expressed in a tissue-speci¢c manner, which
is very suggestive for a functional signi¢cance of these tran-
scripts. In addition, two transcripts were quanti¢ed in several
NF1 patients.
2. Materials and methods
2.1. RNA isolation and cDNA synthesis
RNA was isolated from fresh blood leukocytes (pooled from four
persons), melanocytes (pooled from two persons), ¢broblasts (pooled
from two persons) and short-term lymphocyte cultures using TRIzol
LS Reagent (Invitrogen) according to the manufacturer’s instructions.
Total RNA (2 Wg) was reverse transcribed using SuperScript II Re-
verse transcriptase (Invitrogen) and random hexamers (Amersham
Biosciences). In addition, tissues were obtained as both commercial
cDNA and RNA (brain, heart, kidney, liver, lung, pancreas, placenta,
skeletal muscle), allowing us to compare di¡erent cDNA and RNA
preparations, or only RNA (fetal brain, fetal liver, spinal cord, cer-
ebellum) from Clontech. All commercial cDNAs and RNAs were
pooled from various persons. Cytoplasmic RNA was extracted from
four fresh lymphocyte cultures using the RNeasy mini-kit (Qiagen).
The Oligitex Direct mRNA kit (Qiagen) was used to purify poly(Aþ)
RNA from cytoplasmic RNA.
2.2. Real-time PCR
Primer design, generation of standard curves and quanti¢cation of
splice variants was performed as described [10]. In short, boundary-
spanning primers were designed that speci¢cally recognize and ampli-
fy each splice variant (Table 1), using the Primer Express 1.5 software
(Applied Biosystems). Speci¢city was con¢rmed using a plasmid con-
taining the full-length transcript as template. The boundary spanning
primers, created for ampli¢cation of the shorter transcripts, were not
able to amplify this plasmid, resulting in the absence of a signal. For
generation of the standard curves, PCR products of each spliced and
full-length transcript were run on a 3% TBE agarose gel. The frag-
ments were excised and eluted using QIAquick (Qiagen) spin columns.
The concentrations of the PCR products were measured using the
PicoGreen reagent (Molecular Probes) on a TD-360 £uorometer
(Turner Designs). Absolute standard curves were made based on a
10-fold serial dilution series ranging from 2.4U106 copies to 2.4 cop-
ies. Ampli¢cation reactions contained 1USYBR Green I PCR Mas-
termix (Applied Biosystems) and variable optimized primer concen-
trations (Table 1). The PCR conditions were 95‡C for 10P, followed by
40 cycles of 95‡C for 15Q and Ta (Table 1) for 1P. Melting curves were
0014-5793 / 02 / $22.00 K 2002 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 2 ) 0 2 8 8 7 - 9
*Corresponding author. Fax: (32)-9-240 4970.
E-mail address: ludwine.messiaen@rug.ac.be (L. Messiaen).
Abbreviations: NF1, neuro¢bromatosis type 1; GAP, GTPase-acti-
vating protein
FEBS 26206 19-6-02
FEBS 26206 FEBS Letters 522 (2002) 71^76
generated after ampli¢cation. For each experiment, 100 ng cDNA
(total RNA equivalent), 0.4 ng Clontech cDNA (mRNA equivalent)
or 6 ng cDNA (poly(Aþ) mRNA) were used. Data were collected
using the 5700 SDS thermal cycler (Applied Biosystems). Each sample
was tested in duplicate. For eight tissues, expression levels could be
measured in two independent samples (commercial cDNA or cDNA
prepared in our lab from a di¡erent RNA sample, see Section 2.1).
Data are expressed as the ratio of the copy number for the alternative
transcript to the copy number of the total NF1 expression level (i.e.
the sum of the copy numbers of alternative and full-length tran-
scripts).
2.3. Determination of human^mouse conservation of alternative splicing
Primers were designed to simultaneously amplify both transcripts
(with or without alternative exon) in the same reaction (Table 1). PCR
conditions were 35 cycles of 92‡C 1P, Ta 50Q and 72‡C 1P on a PTC-
200 thermal cycler (BIOzym). The PCR products were cloned in the
pCR-2.1-TOPO vector (Invitrogen) and transformed into TOP-10FP
cells. The colonies were lysed and the subcloned fragments were ream-
pli¢ed with the same primers. The length of each clone was veri¢ed by
agarose gel electrophoresis. Mouse tissues (mouse heart, brain, spleen,
lung, liver, skeletal muscle, kidney and testis) were obtained as cDNA
from Clontech. In addition, real-time PCR using boundary spanning
primers (Table 1) was performed in order to screen for the NF1-vE43
variant.
3. Results and discussion
3.1. Quanti¢cation of splice variants
Selection of transcript variants for further study [deletion of
respectively exon 4b (NF1-vE4b), exon 33 (NF1-vE33), exon
37 (NF1-vE37), exon 43 (NF1-vE43) and exon 45 (NF1-
vE45)] was based on a semi-quantitative study, whereby
PCR products were separated on an ALF-express automated
DNA sequencer. In addition, we investigated four splice var-
iants already reported in literature: the insertion of 31 bp
between exon 4a and 4b (exon 4a-2, NF1-insE4a-2) [11,12]
and the deletion of exon 29, exon 30 and exon 29/30 (NF1-
vE29, NF1-vE30, NF1-vE29/30) [7]. To investigate the sig-
ni¢cance of these variants a real-time PCR assay was devel-
oped for accurate quanti¢cation of the transcript levels based
on speci¢c ampli¢cation of NF1-splice variants using well-val-
idated boundary spanning primers. Absolute standard curves
over a wide dynamic range were generated using a dilution
series of £uorometrically quanti¢ed PCR products [10]. Ex-
pression of the di¡erent splice variants was investigated in
several tissues (Table 2). Comparison of fetal brain and liver
with adult brain and liver expression levels indicates that
splicing may be di¡erentially regulated during di¡erentiation
in these tissues. Four transcripts show a low expression level
(6 1%: NF1-vE29, NF1-vE29/30, NF1-vE33 and NF1-
vE45) of which a few are expressed in a tissue-speci¢c man-
ner. Three are moderately low expressed (9 2.5%: NF1-in-
sE4a-2, NF1-vE30, NF1-vE37) and two exhibit a remarkably
high expression in speci¢c tissues (5^22%: NF1-vE4b, NF1-
vE43). Determination of the intra-assay variability on calcu-
lated quantities for duplicated samples of all tissues showed a
good reproducibility. Median coe⁄cient of variation (CV) for
full-length transcripts was 7.2%. PCR reproducibility for very
low copy numbers is in£uenced by distribution statistics (Pois-
son’s law) and small di¡erences in ampli¢cation e⁄ciency
which can be seen in the larger median CV-value for dupli-
cated samples of the variant transcripts (CV=19.4%), as some
of these are expressed in low amounts. In addition, interassay
variability on the calculated percentages of each variant was
assessed using two di¡erent cDNA samples prepared from the
same RNA sample (median CV=13.6%). Furthermore, the
availability of two cDNA samples for eight tissues (commer-
cial cDNA versus cDNA prepared in our lab) derived from
di¡erent RNA samples gave us the opportunity to compare
interassay variability on the calculated percentages between
di¡erent RNA and cDNA preparations. As expected, the
highest level of variability was observed in this last group
(median CV=24.2%).
3.2. Interpretation of the quantitative data
The functional signi¢cance of the low to moderately low
expressed transcripts constituting 6 2.5% of the total NF1
expression level is unclear. Di¡erent explanations can be given
for this low level of expression. First of all, these low ex-
Table 1
Sequences, quantities and annealing temperatures of primer pairs
Amplicon Forward primer Reverse primer Primer
quantity
(nM)
Annealing
temperature
(Ta, ‡C)
NF1-v4a-2 agtctttagtcgcatttctaccaggtta ttgtcttctgaacaaacagttaattcct 300 60
NF1-ex4a-2 gcatttctaccagtaaccttgatgatac tctgaacaaacagttaattcctgtaacc 300 60
NF1-v4b cgcatttctaccagaaacagcat tgctaactgcgcaaccttctt 100 62
NF1-ex33 cacacatggactggtcattaatatca tcaaaacttgcttggtctcttcac 300 60
NF1-v33 tgtagctttggcttctggaaatg caaaacttgcttggtctcttcttg 300 60
NF1-ex29/30 gcagttctgacccgagtttacg atgtctctagtaactggccctcgat 200 60
NF1-v29 agacaccaaagtttctattaaagtcagct ggtacaagttaaggcacacagaagatta 200 60
NF1-v30 tctgacccgagtttacggtattg agatttgacagccatggagtcat 200 60
NF1-v29/30 caaagacaccaaagtttctattaaagtattg ggagtcatgtattccaaacaaaggt 200 60
NF1-ex37 acgagtgtctcatgggcagat actgttgtaagtgtcaggtccttttaag 100 62, 3% DMSO
NF1-v37 cttgttgtctttgggtgtattagca gcagaggcgagtccttgc 100 62, 3% DMSO
NF1-ex43 tgaggagagtagcagaaactgattatg cgtaaatgtgggtgctgttgtg 300 62
NF1-v43 gcaaccttctcaggccaaca ggaaatcctctgagtttcaagca 300 62
NF1-ex45 aagtctttcctgttgtgcataatttg caatgataacagggtgttgatcttaga 250 62
NF1-v45 gctgcttcttactgttctagcataattt taacagggtgttgatcttagagtcca 250 62
mNF1-v43 acagccttctcaggccaaca ggaatcctttgggtttcaagca 300 62
mNF1-ex43 tgagaagagtggcagagactgactatg cgtaaatgtgggtgctgctg 300 62
mNF1+/3ex37 ctcttgtggtgtttggctgtattagc ggactcttgtcattgaatatccggag 300 62
mNF1+/3ex4b atctgccattttcttcacacctgc ccggataattttctacccagttcc 300 62
mNF1+/3ex43 aaaccagtccccgagcca gcaaaccgccataagccatt 300 62
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pressed transcripts might represent ‘noise’, caused by e.g. the
relaxation of the RNA splicing machinery. In that case it
would be expected that the error rate is similar in all tissues.
However, some of the variants show a tissue-speci¢c expres-
sion pattern (e.g. NF1-vE29, NF1-vE45) or are expressed
signi¢cantly higher in speci¢c tissues (e.g. NF1-insE4a-2,
NF1-vE37). Our study con¢rms some of the previous expres-
sion data for NF1-vE29, NF1-vE30 and NF1-vE29/30 splice
variants in human tissues, but considerably extends those ob-
servations by investigating the expression in a larger number
of tissues using a more sensitive and quantitative real-time
PCR technique. The NF1-vE29 transcript, described as being
brain-speci¢c [7], was con¢rmed to exhibit the highest expres-
sion in brain and cerebellum. In addition, our study demon-
strates a high expression in spinal cord and a low level of
expression in other tissues, probably escaping detection on
conventional low-sensitivity agarose-based gel electrophoresis
[7]. The agreement of our study with a previous one demon-
strating a signi¢cant di¡erence in variant expression between
tissues strengthens the possibility that these transcripts are not
the result of noise. Although the NF1-vE29, NF1-vE29/30
and NF1-vE30 variants were reported in a qualitative RT-
PCR study [7], we now demonstrate that they account for
only a minor proportion of the total NF1 mRNA. This clearly
demonstrates that caution has to be taken for interpretation
of non-quantitative PCR end-point results.
Secondly, the variants could represent ‘true’ functional NF1
isoforms required in low amounts and might actually have a
subtle, yet important biological role in the development of
complex organisms. Since the number of genes in humans is
roughly only double that of Caenorhabditis elegans and alter-
native splicing probably plays a role in the creation of species
diversity, it can be expected that studies in other genes will
reveal similar results. Due to the lack of sensitivity of the
commonly used quanti¢cation techniques (e.g. Northern blot-
ting, RNase protection analysis), the very low expressed var-
iants escape detection. Three recent studies using a similar
approach [13^15] also publish data on splice variants (for
Jun kinases, 5-HT4 receptors and rat carnitine transporter
OCTN2) with expression values of less than 1% of the total
transcripts.
A third explanation for the low percentages of alternative
NF1 transcripts might be that expression levels of a speci¢c
variant is high in some cells of a speci¢c tissue, but due to
pooling of transcripts when preparing RNA from all cells,
these transcripts become only a minor fraction of the total.
This interpretation is supported by staining patterns of neuro-
¢bromin, where it has been shown that the intensity between
individual neurons varies dramatically [16,17]. Furthermore,
nuclear localization was also seen only in a subset of these
neurons and in a subset of NIH3T3 ¢broblast cells [16,18]. In
cultured keratinocytes a small subpopulation of cells was in-
tensively stained for NF1 protein, whereas the majority of
cells displayed only a weak immunoreaction [19]. Di¡erences
in immunoreactivity may re£ect di¡erences in physiological
state, which could in£uence the expression of speci¢c NF1
variants. Microdissection followed by quanti¢cation in indi-
vidual cells might shed more light on this phenomenon.
Two transcripts (NF1-vE4b, NF1-vE43) displayed high ex-
pression in speci¢c tissues. Interestingly, exon 4b represents a
mutational hotspot in NF1. NF1-vE4b results from an out of
frame skip of exon 4b and would lead to a premature stop
codon. This variant was most highly expressed in blood
(5.0%), heart (2.3%) and cerebellum (2.3%), but was also ex-
pressed often in several other tissues (Table 2). Skipping of
this exon in blood from non-a¡ected people was also de-
scribed by other groups [12,20] and was shown not to be
induced by cold shock. Translation of this variant would
lead to a short protein of 163 amino acids lacking the central
GAP-related domain involved in the down regulation of RAS
[21,22] and hence might be involved in the upregulation of the
RAS pathways in di¡erent tissues or developmental stages.
Deletion of exon 43 (NF1-vE43) is an in-frame event. The
NF1-vE43 variant had a very high expression in lung, liver,
placenta, fetal liver, kidney and skeletal muscle (Fig. 1). Lung,
liver and kidney neuro¢bromin expression is higher during
development than in the adult, where expression is barely
detectable [16,18]. Skeletal muscle shows a strong expression
during development and almost no detectable signal in adults.
It is of special interest that NF1-vE43 is highly expressed
(relative to the general NF1 expression level) in those tissues
where neuro¢bromin becomes downregulated during late fetal
and early postnatal development. We hypothesize that this
variant might have a speci¢c function in these tissues. It is
Table 2
Quantity (in percentage) in various tissues of nine splice variants of the NF1 gene
Tissue Splice variants (%)
NF1-insE4a-2 NF1-vE4b NF1-vE29 NF1-vE30 NF1-vE29/30 NF1-vE33 NF1-vE37 NF1-vE43 NF1-vE45
blood 1.349 5.032 0.016 1.688 0.055 0.263 0.204 4.286 0.117
fetal brain 1.287 1.493 0.099 0.078 0.125 0.091 0.039 0.754 0.086
brain 0.614 1.932 0.185 0.050 0.204 0.111 0.243 2.873 n.d.
heart 0.527 2.269 0.080 0.462 0.709 0.465 1.074 4.298 n.d.
kidney 0.242 1.054 0.021 0.515 0.158 0.167 0.305 11.650 n.d.
fetal liver 0.395 1.901 n.d. 0.495 0.046 0.699 0.637 21.956 0.077
liver 0.489 1.202 0.017 1.234 0.131 0.329 1.326 15.557 n.d.
lung 0.244 1.832 0.034 0.953 0.049 0.465 0.864 6.246 0.512
pancreas 0.265 1.540 0.063 0.216 n.d. 0.919 0.214 2.238 n.d.
placenta 0.493 0.897 n.d. 0.920 0.397 0.402 0.478 7.952 0.043
skeletal muscle n.d. 1.741 n.d. n.d. n.d. 0.498 2.111 14.307 n.d.
melanocytes 0.263 0.825 n.d. 0.456 0.027 0.263 0.246 1.578 0.139
spinal cord 0.486 1.281 0.253 0.154 0.121 0.133 0.175 2.518 0.007
cerebellum 0.878 2.347 0.136 0.500 0.274 0.096 0.032 1.127 0.011
¢broblasts 0.551 0.876 0.025 0.604 0.016 0.170 1.340 3.052 n.d.
In bold: expression of s 5%; in italics: expression of 1^5%; regular letter type: expression of 6 1%; n.d. no expression of the variant could
be detected.
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noteworthy that these tissues are not typically associated with
NF1 pathogenesis. Likewise, the expression of another NF1
isoform was described as muscle-speci¢c, whereas this tissue is
rarely a¡ected in NF1 patients [5,23]. The expression of splice
variants in tissues not commonly associated with NF1 pathol-
ogy raises the question about uncharacterized diseases result-
ing from defects in the NF1 gene, but with a di¡erent clinical
phenotype than NF1. In light of this it is interesting to note
that until now no mutation has been found in the alternative
exons 9br, 23a and 48a [24^26]. Mutations in exon 43 are also
extremely underrepresented with only 2 mutations reported
until now [26]. In silico analysis using PROSITE (http://
www.expasy.ch/prosite/) revealed that exon 43 contains a bi-
partite nuclear localization signal. Hence a neuro¢bromin
translated from this transcript might be functionally di¡erent
from full-length neuro¢bromin and may be excluded from
nuclear localization. Neuro¢bromin staining in the nucleus
has so far been reported for developing neurons [27], in a
subset of neurons in adult rat root ganglia [16], in a subset
of NIH3T3 ¢broblasts [18] and in di¡erentiating keratinocytes
[19]. The lower expression of the NF1-vE43 transcript in neu-
ral tissues versus non-neural tissues might indicate that, if this
isoform lacking the nuclear localization signal is formed, nu-
clear targeting may be important in neural tissues. Up- or
downregulation of di¡erent NF1 isoforms could in£uence
the activity and localization of neuro¢bromin. Antibodies
are now being generated against this region in order to char-
acterize this form at the protein level. Further studies will be
performed to reveal the localization and function of this var-
iant.
During the ¢nalization of this manuscript an independent
study was published also detecting the NF1-vE43 variant in
fresh blood, in blood using the PAXgene blood RNA tubes,
which stabilizes and protects RNA from degradation, and in
several tissues, but these analyses were not performed in a
quantitative manner [28].
3.3. Quanti¢cation of NF1-vE43 and NF1-vE4b in
NF1 patients
The complex pattern of alternative splicing might provide
insights into the extreme phenotypical variability between pa-
tients, even among a¡ected members of the same family. The
splicing machinery could act as a potential genetic modi¢er.
Interindividual di¡erences in the expression or stability of the
di¡erent NF1 variants could in£uence the phenotypic expres-
sion of NF1 mutations. Di¡erences in the ratio of alternatively
spliced transcripts can arise from variations in certain splicing
factors or from SNPs situated in splicing enhancers or si-
lencers [29]. We explored this hypothesis by quanti¢cation
Fig. 1. Expression pro¢les for NF1-vE43 in several human tissues.
Table 3
Quanti¢cation of NF1-vE4b and NF1-vE43 in lymphocyte cultures from NF1 patients and healthy control samples
Type Mutation E¡ect on cDNA Amino acid change % NF1-vE4b % NF1-vE43
Nonsense 574CsT 574CsT R192X 3.95 11.03
Nonsense 625CsT 625CsT Q209X 2.22 11.11
Nonsense 910CsT 910CsT R304X 1.44 14.00
Nonsensea 3826CsT 3826CsT R1276X 1.12 3.60
Nonsensea 3826CsT 3826CsT R1276X 1.20 11.80
Nonsense 4084CsT 4084CsT R1362X 1.40 4.66
Deletion 819^821delCCT 819^821delCCT frameshift 2.41 8.48
Deletion 1756^1759delACTA 1756^1759delACTA frameshift 2.71 6.01
Deletion 3457^3460delCTCA 3457^3460delCTCA frameshift 2.31 8.39
Deletion 5717delT 5717delT frameshift 4.87 5.06
Large deletion total gene deletion ^ ^ 2.92 7.00
Splice 1261^19GsA 1261^17ins17 frameshift 2.58 3.74
Splice 1466AsG 1466^1527del62 Y489C 1.50 3.82
Splice 1885GsA 1846^1886del41 frameshift 2.93 5.87
Splice 2990+3AsC 2851^2990del140 frameshift 3.43 3.27
Missenseb 4267AsG 4267AsG K1423E 1.86 7.31
Missenseb 4267AsG 4267AsG K1423E 1.20 5.21
Insertionc 2585insA 2585insA frameshift 3.34 4.25
Insertionc 2585insA 2585insA frameshift 2.24 5.21
Duplication dupl23-2 dupl23-2 frameshift 2.42 3.05
Mean of 23 control samples ^ ^ ^ 3.11 5.83
aNon-related patients carrying an identical mutation.
bRelated patients carrying an identical mutation.
cDi¡erent lymphocyte cultures from the same patient.
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of NF1-vE43 and NF1-vE4b in RNA freshly extracted from
short-term lymphocyte cultures of 19 NF1 patients and 23
control subjects. Patients with di¡erent mutation types, in-
cluding nonsense, frameshift, missense, insertions, deletions
and splice site mutations were selected. Two independent lym-
phocyte cultures, established from the same NF1 patient
(2585insA), two cultures from a¡ected members of the same
family (4267AsG) and two cultures from non-related NF1-
patients carrying an identical mutation (3826CsT) were in-
cluded. Mean quantities for 23 normal lymphocyte cultures
for NF1-vE43 and NF1-vE4b are 5.8% and 3.1%, respectively
(Table 3). These values di¡er slightly from measurements of
RNA extracted immediately from blood and may be attrib-
uted to the di¡erent multi-cellular composition of lympho-
cytes isolated directly from blood in comparison with short-
term lymphocyte cultures in which selection for T-cells occurs.
Variability is observed between di¡erent individuals, but com-
parable results are obtained for the two independent cultures
established from the same NF1 patient (Table 3). Markedly,
ratios higher than 10% for NF1-vE43 all correspond to NF1
patients carrying nonsense mutations. However, a possible
correlation was not found using statistical analysis. Moreover,
two samples of the control group have similar values (individ-
ual data not shown), and two non-related NF1 patients carry-
ing an identical nonsense mutation (3826CsT) exhibit con-
siderably di¡erent expression ratios, con¢rming the lack of
correlation. As a conclusion, these quantitative data clearly
demonstrate interindividual variations in the expression ratio
of NF1-vE43 and NF1-vE4b.
Mutation analysis of NF1 gene has shown that about 30%
of NF1 patients carry a splice mutation resulting in the pro-
duction of one or several shortened transcripts [24^26]. Some
of the variants quanti¢ed in this study are identical to mis-
spliced transcripts constitutively formed by speci¢c genomic
NF1 mutations in patients (e.g. NF1-vE29, NF1-vE29/30 and
NF1-vE37) [24,25]. Factors modifying the splicing e⁄ciency
might also cause variation in the levels of the aberrantly
spliced transcripts transcribed from the mutated allele. Dis-
ease variability among cystic ¢brosis patients carrying splicing
mutations has been shown to be associated with varying levels
of normally and aberrantly spliced CFTR transcripts. In in-
dividuals carrying the 5T allele in intron 8 of the CFTR gene,
which can lead to exon 9 skipping, an extreme variability in
the level of exon 9 splicing is observed in conjunction with a
variable phenotype in the patients [30]. This has also been
described for the 3849+10 kb CCT mutation, leading to an
active splice site in intron 19 of the CFTR gene, which can
lead to the insertion of a 84-bp ‘exon’. Variability in the rel-
ative amounts of splicing factors probably contributes to the
di¡erent patterns of alternative splicing found among di¡erent
individuals and hence to the variation in disease severity
[31,32]. It would be interesting to analyze mutated transcripts
in NF1 patients carrying an identical mutation in order to
examine this hypothesis.
3.4. Demonstration that NF1-vE4b, NF1-vE37 and NF1-vE43
are bona ¢de transcripts
RNA polymerase II transcripts are subjected to polyadeny-
lation, which has a function in mRNA stabilization, nuclear
export and translation. In order to demonstrate that NF1-
vE4b, NF1-vE37 and NF1-vE43 are bona ¢de transcripts,
cytoplasmic RNA was extracted from lymphocyte cultures
of four healthy individuals and poly(Aþ) mRNA was puri¢ed.
Real-time PCR quanti¢cation results demonstrated the pres-
ence of these transcripts (NF1-vE4b: 3.7%, NF1-vE37: 0.9%,
and NF1-vE43: 4.3%), con¢rming that they are polyadeny-
lated and e⁄ciently transported to the cytoplasm.
3.5. Determination of conservation of NF1-vE4b, NF1-vE37
and NF1-vE43 variants in mouse
To determine human^mouse conservation of variant ex-
pression of NF1-vE4b, NF1-vE37 and NF1-vE43, PCR was
performed on mouse cDNA samples (NF1-vE4b: heart and
lung; NF1-vE37: heart and skeletal muscle; NF1-vE43: lung
and kidney). Primers were designed so that the full-length and
skipped transcripts could be ampli¢ed simultaneously (Table
1). PCR products were cloned and 200 colonies per tissue
were lysed and reampli¢ed with the same primers. Products
were separated by agarose gel electrophoresis in order to iden-
tify a shorter transcript corresponding to the size of the exon-
deleted transcript. None of the clones corresponded to this
size.
In addition, real-time PCR using boundary-spanning prim-
ers adapted to the mouse NF1 sequence were used for quan-
ti¢cation of mouse NF1-vE43 (Table 1). Eight mouse tissues
(heart, brain, spleen, lung, liver, skeletal muscle, kidney and
testis) were screened for the presence of the NF1-vE43 tran-
script. Real-time PCR resulted in good ampli¢cation curves
for the full-length transcript, but no signal was obtained after
40 ampli¢cation cycles for the transcript lacking exon 43.
It can be concluded that these variants are not conserved in
mouse. This is in agreement with previously published dis-
crepancies of NF1 processing between humans and rodents.
Inclusion of exon 23b [33] was found in mouse and rat, but
not in humans. The NF1-vE29/30 and NF1-vE29 was only
seen in humans and NF1-vE30 was seen in rat, but not in
mouse [7]. These variants might account for species-speci¢c
di¡erences. A recent study on mouse and human ESTs [34]
revealed that only 11% of the detected alternative splice pairs
were conserved, suggesting that a substantial fraction of alter-
native splicing events may be species speci¢c. Alternative
splicing is regulated by a complex mechanism involving di¡er-
ent trans-acting factors, binding on cis-elements that may be
species-, tissue- and developmental stage-speci¢c.
4. Conclusion
This study provides a detailed examination of the expres-
sion patterns of nine NF1 splice variants across a variety of
human tissues using a quantitative real-time PCR strategy.
Several novel splice variants were shown to be highly ex-
pressed in speci¢c tissues. These variants might shed more
light on possible unknown functional domains and might ex-
pand our understanding of the role of neuro¢bromin. The
NF1-vE43 variant might play an important role, as it is
highly expressed in speci¢c tissues and it misses the nuclear
localization signal. Further studies are required to character-
ize these variants at the protein level, and it will be a challenge
to investigate whether quantitative di¡erences between var-
iants might play a role in phenotypic variability among NF1
patients.
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